nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemfibrozil—CYP3A4—bone cancer	0.811	1	CbGaD
Gemfibrozil—SLCO1B1—Methotrexate—bone cancer	0.00916	0.613	CbGbCtD
Gemfibrozil—CYP2C9—Cisplatin—bone cancer	0.00417	0.279	CbGbCtD
Gemfibrozil—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00413	0.0507	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00341	0.0419	CbGpPWpGaD
Gemfibrozil—PPARA—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00325	0.0399	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00319	0.0392	CbGpPWpGaD
Gemfibrozil—PPARA—Nuclear Receptors—NR1I2—bone cancer	0.00297	0.0365	CbGpPWpGaD
Gemfibrozil—PPARA—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00235	0.0289	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.00218	0.0268	CbGpPWpGaD
Gemfibrozil—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00195	0.024	CbGpPWpGaD
Gemfibrozil—PPARA—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.0019	0.0233	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00187	0.0229	CbGpPWpGaD
Gemfibrozil—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00186	0.0229	CbGpPWpGaD
Gemfibrozil—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00174	0.0214	CbGpPWpGaD
Gemfibrozil—PPARA—Estrogen Receptor Pathway—JUN—bone cancer	0.00164	0.0201	CbGpPWpGaD
Gemfibrozil—PPARA—Orphan transporters—TUBB4B—bone cancer	0.00163	0.02	CbGpPWpGaD
Gemfibrozil—CYP3A4—Doxorubicin—bone cancer	0.00162	0.109	CbGbCtD
Gemfibrozil—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00159	0.0195	CbGpPWpGaD
Gemfibrozil—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00152	0.0186	CbGpPWpGaD
Gemfibrozil—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00152	0.0186	CbGpPWpGaD
Gemfibrozil—Bacterial infection—Methotrexate—bone cancer	0.00151	0.0164	CcSEcCtD
Gemfibrozil—PPARA—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00149	0.0183	CbGpPWpGaD
Gemfibrozil—PPARA—PPAR Alpha Pathway—CDK4—bone cancer	0.00146	0.0179	CbGpPWpGaD
Gemfibrozil—PPARA—Orphan transporters—TUBB2A—bone cancer	0.00141	0.0173	CbGpPWpGaD
Gemfibrozil—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00136	0.0167	CbGpPWpGaD
Gemfibrozil—Peripheral vascular disorder—Epirubicin—bone cancer	0.00133	0.0144	CcSEcCtD
Gemfibrozil—Pain—Carboplatin—bone cancer	0.00132	0.0143	CcSEcCtD
Gemfibrozil—Peripheral vascular disorder—Doxorubicin—bone cancer	0.00123	0.0133	CcSEcCtD
Gemfibrozil—PPARA—Generic Transcription Pathway—ZNF77—bone cancer	0.0012	0.0147	CbGpPWpGaD
Gemfibrozil—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00105	0.0129	CbGpPWpGaD
Gemfibrozil—Myasthenia—Epirubicin—bone cancer	0.00104	0.0113	CcSEcCtD
Gemfibrozil—Bone marrow depression—Methotrexate—bone cancer	0.00103	0.0112	CcSEcCtD
Gemfibrozil—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000985	0.0121	CbGpPWpGaD
Gemfibrozil—Bone marrow depression—Epirubicin—bone cancer	0.000966	0.0105	CcSEcCtD
Gemfibrozil—Myasthenia—Doxorubicin—bone cancer	0.00096	0.0104	CcSEcCtD
Gemfibrozil—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000941	0.0116	CbGpPWpGaD
Gemfibrozil—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000905	0.0111	CbGpPWpGaD
Gemfibrozil—Bone marrow depression—Doxorubicin—bone cancer	0.000894	0.00969	CcSEcCtD
Gemfibrozil—Neuritis—Epirubicin—bone cancer	0.000873	0.00947	CcSEcCtD
Gemfibrozil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000858	0.0105	CbGpPWpGaD
Gemfibrozil—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00084	0.0103	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000839	0.0103	CbGpPWpGaD
Gemfibrozil—Breast disorder—Cisplatin—bone cancer	0.000833	0.00903	CcSEcCtD
Gemfibrozil—Hyperaesthesia—Epirubicin—bone cancer	0.000831	0.00901	CcSEcCtD
Gemfibrozil—Nasopharyngitis—Cisplatin—bone cancer	0.000824	0.00894	CcSEcCtD
Gemfibrozil—Neuritis—Doxorubicin—bone cancer	0.000808	0.00877	CcSEcCtD
Gemfibrozil—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000808	0.00993	CbGpPWpGaD
Gemfibrozil—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000782	0.00961	CbGpPWpGaD
Gemfibrozil—Pancreatitis—Cisplatin—bone cancer	0.000781	0.00847	CcSEcCtD
Gemfibrozil—Hyperaesthesia—Doxorubicin—bone cancer	0.000769	0.00834	CcSEcCtD
Gemfibrozil—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000766	0.00941	CbGpPWpGaD
Gemfibrozil—Pancytopenia—Cisplatin—bone cancer	0.000756	0.00821	CcSEcCtD
Gemfibrozil—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000749	0.0092	CbGpPWpGaD
Gemfibrozil—Jaundice cholestatic—Epirubicin—bone cancer	0.000742	0.00805	CcSEcCtD
Gemfibrozil—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000737	0.00905	CbGpPWpGaD
Gemfibrozil—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000733	0.009	CbGpPWpGaD
Gemfibrozil—Vasculitis—Methotrexate—bone cancer	0.000714	0.00774	CcSEcCtD
Gemfibrozil—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000712	0.00875	CbGpPWpGaD
Gemfibrozil—Renal failure—Cisplatin—bone cancer	0.000698	0.00757	CcSEcCtD
Gemfibrozil—Neuropathy peripheral—Cisplatin—bone cancer	0.000696	0.00755	CcSEcCtD
Gemfibrozil—Blood bilirubin increased—Epirubicin—bone cancer	0.000689	0.00748	CcSEcCtD
Gemfibrozil—Jaundice cholestatic—Doxorubicin—bone cancer	0.000687	0.00745	CcSEcCtD
Gemfibrozil—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000683	0.00839	CbGpPWpGaD
Gemfibrozil—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000682	0.00838	CbGpPWpGaD
Gemfibrozil—Hepatobiliary disease—Cisplatin—bone cancer	0.000672	0.00729	CcSEcCtD
Gemfibrozil—Musculoskeletal pain—Epirubicin—bone cancer	0.00066	0.00716	CcSEcCtD
Gemfibrozil—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000655	0.00804	CbGpPWpGaD
Gemfibrozil—Phosphatase alkaline increased—Epirubicin—bone cancer	0.000652	0.00707	CcSEcCtD
Gemfibrozil—Blood bilirubin increased—Doxorubicin—bone cancer	0.000638	0.00692	CcSEcCtD
Gemfibrozil—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000629	0.00773	CbGpPWpGaD
Gemfibrozil—Connective tissue disorder—Cisplatin—bone cancer	0.000626	0.0068	CcSEcCtD
Gemfibrozil—Colitis—Epirubicin—bone cancer	0.000626	0.00679	CcSEcCtD
Gemfibrozil—PPARA—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.000612	0.00752	CbGpPWpGaD
Gemfibrozil—Musculoskeletal pain—Doxorubicin—bone cancer	0.000611	0.00662	CcSEcCtD
Gemfibrozil—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.000603	0.00654	CcSEcCtD
Gemfibrozil—Eye disorder—Cisplatin—bone cancer	0.000596	0.00646	CcSEcCtD
Gemfibrozil—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000584	0.00717	CbGpPWpGaD
Gemfibrozil—Colitis—Doxorubicin—bone cancer	0.000579	0.00628	CcSEcCtD
Gemfibrozil—PPARA—Gene Expression—ZNF77—bone cancer	0.000577	0.00709	CbGpPWpGaD
Gemfibrozil—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000577	0.00709	CbGpPWpGaD
Gemfibrozil—Photosensitivity—Methotrexate—bone cancer	0.000576	0.00625	CcSEcCtD
Gemfibrozil—Mediastinal disorder—Cisplatin—bone cancer	0.000575	0.00623	CcSEcCtD
Gemfibrozil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000566	0.00695	CbGpPWpGaD
Gemfibrozil—Alopecia—Cisplatin—bone cancer	0.000563	0.00611	CcSEcCtD
Gemfibrozil—Flatulence—Cisplatin—bone cancer	0.000547	0.00593	CcSEcCtD
Gemfibrozil—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000544	0.0059	CcSEcCtD
Gemfibrozil—Photosensitivity—Epirubicin—bone cancer	0.000539	0.00585	CcSEcCtD
Gemfibrozil—Dermatitis exfoliative—Methotrexate—bone cancer	0.000536	0.00581	CcSEcCtD
Gemfibrozil—Eczema—Epirubicin—bone cancer	0.000527	0.00571	CcSEcCtD
Gemfibrozil—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000526	0.00646	CbGpPWpGaD
Gemfibrozil—Vision blurred—Cisplatin—bone cancer	0.000523	0.00567	CcSEcCtD
Gemfibrozil—Anaemia—Cisplatin—bone cancer	0.000513	0.00556	CcSEcCtD
Gemfibrozil—PPARA—Circadian rythm related genes—GNA11—bone cancer	0.000505	0.00621	CbGpPWpGaD
Gemfibrozil—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000503	0.00546	CcSEcCtD
Gemfibrozil—PPARA—Circadian rythm related genes—EZH2—bone cancer	0.000503	0.00618	CbGpPWpGaD
Gemfibrozil—Dermatitis exfoliative—Epirubicin—bone cancer	0.000502	0.00544	CcSEcCtD
Gemfibrozil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000501	0.00616	CbGpPWpGaD
Gemfibrozil—Photosensitivity—Doxorubicin—bone cancer	0.000499	0.00541	CcSEcCtD
Gemfibrozil—Leukopenia—Cisplatin—bone cancer	0.000497	0.00539	CcSEcCtD
Gemfibrozil—Eczema—Doxorubicin—bone cancer	0.000487	0.00529	CcSEcCtD
Gemfibrozil—Convulsion—Cisplatin—bone cancer	0.000481	0.00522	CcSEcCtD
Gemfibrozil—Myalgia—Cisplatin—bone cancer	0.000472	0.00513	CcSEcCtD
Gemfibrozil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000469	0.00509	CcSEcCtD
Gemfibrozil—Liver function test abnormal—Methotrexate—bone cancer	0.000467	0.00506	CcSEcCtD
Gemfibrozil—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000464	0.00503	CcSEcCtD
Gemfibrozil—Breast disorder—Methotrexate—bone cancer	0.000457	0.00496	CcSEcCtD
Gemfibrozil—Oedema—Cisplatin—bone cancer	0.000453	0.00491	CcSEcCtD
Gemfibrozil—Anaphylactic shock—Cisplatin—bone cancer	0.000453	0.00491	CcSEcCtD
Gemfibrozil—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00045	0.00554	CbGpPWpGaD
Gemfibrozil—Nervous system disorder—Cisplatin—bone cancer	0.000444	0.00482	CcSEcCtD
Gemfibrozil—Thrombocytopenia—Cisplatin—bone cancer	0.000443	0.00481	CcSEcCtD
Gemfibrozil—Skin disorder—Cisplatin—bone cancer	0.00044	0.00477	CcSEcCtD
Gemfibrozil—Liver function test abnormal—Epirubicin—bone cancer	0.000437	0.00474	CcSEcCtD
Gemfibrozil—Eosinophilia—Methotrexate—bone cancer	0.000433	0.00469	CcSEcCtD
Gemfibrozil—Abdominal pain upper—Epirubicin—bone cancer	0.000432	0.00469	CcSEcCtD
Gemfibrozil—Pancreatitis—Methotrexate—bone cancer	0.000429	0.00465	CcSEcCtD
Gemfibrozil—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000428	0.00526	CbGpPWpGaD
Gemfibrozil—Breast disorder—Epirubicin—bone cancer	0.000428	0.00464	CcSEcCtD
Gemfibrozil—Nasopharyngitis—Epirubicin—bone cancer	0.000423	0.00459	CcSEcCtD
Gemfibrozil—Muscular weakness—Epirubicin—bone cancer	0.000417	0.00453	CcSEcCtD
Gemfibrozil—Pancytopenia—Methotrexate—bone cancer	0.000415	0.0045	CcSEcCtD
Gemfibrozil—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000413	0.00448	CcSEcCtD
Gemfibrozil—Paraesthesia—Cisplatin—bone cancer	0.000407	0.00441	CcSEcCtD
Gemfibrozil—PPARA—Generic Transcription Pathway—NR1I2—bone cancer	0.000406	0.00499	CbGpPWpGaD
Gemfibrozil—Eosinophilia—Epirubicin—bone cancer	0.000405	0.00439	CcSEcCtD
Gemfibrozil—Liver function test abnormal—Doxorubicin—bone cancer	0.000404	0.00439	CcSEcCtD
Gemfibrozil—Erectile dysfunction—Methotrexate—bone cancer	0.000403	0.00437	CcSEcCtD
Gemfibrozil—Pancreatitis—Epirubicin—bone cancer	0.000401	0.00435	CcSEcCtD
Gemfibrozil—Abdominal pain upper—Doxorubicin—bone cancer	0.0004	0.00434	CcSEcCtD
Gemfibrozil—Photosensitivity reaction—Methotrexate—bone cancer	0.000399	0.00433	CcSEcCtD
Gemfibrozil—PPARA—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000398	0.00489	CbGpPWpGaD
Gemfibrozil—Breast disorder—Doxorubicin—bone cancer	0.000396	0.00429	CcSEcCtD
Gemfibrozil—Nasopharyngitis—Doxorubicin—bone cancer	0.000392	0.00425	CcSEcCtD
Gemfibrozil—Gastrointestinal disorder—Cisplatin—bone cancer	0.000391	0.00424	CcSEcCtD
Gemfibrozil—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000391	0.0048	CbGpPWpGaD
Gemfibrozil—Depression—Methotrexate—bone cancer	0.000389	0.00422	CcSEcCtD
Gemfibrozil—Pancytopenia—Epirubicin—bone cancer	0.000388	0.00421	CcSEcCtD
Gemfibrozil—Pain—Cisplatin—bone cancer	0.000387	0.0042	CcSEcCtD
Gemfibrozil—Muscular weakness—Doxorubicin—bone cancer	0.000386	0.00419	CcSEcCtD
Gemfibrozil—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000386	0.00474	CbGpPWpGaD
Gemfibrozil—Renal failure—Methotrexate—bone cancer	0.000383	0.00416	CcSEcCtD
Gemfibrozil—Eosinophilia—Doxorubicin—bone cancer	0.000375	0.00406	CcSEcCtD
Gemfibrozil—Photosensitivity reaction—Epirubicin—bone cancer	0.000373	0.00405	CcSEcCtD
Gemfibrozil—Feeling abnormal—Cisplatin—bone cancer	0.000373	0.00405	CcSEcCtD
Gemfibrozil—Pancreatitis—Doxorubicin—bone cancer	0.000371	0.00403	CcSEcCtD
Gemfibrozil—Weight decreased—Epirubicin—bone cancer	0.00037	0.00401	CcSEcCtD
Gemfibrozil—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000369	0.00453	CbGpPWpGaD
Gemfibrozil—Hepatobiliary disease—Methotrexate—bone cancer	0.000369	0.004	CcSEcCtD
Gemfibrozil—Pancytopenia—Doxorubicin—bone cancer	0.000359	0.0039	CcSEcCtD
Gemfibrozil—Renal failure—Epirubicin—bone cancer	0.000358	0.00389	CcSEcCtD
Gemfibrozil—Neuropathy peripheral—Epirubicin—bone cancer	0.000357	0.00388	CcSEcCtD
Gemfibrozil—Jaundice—Epirubicin—bone cancer	0.000355	0.00386	CcSEcCtD
Gemfibrozil—Urinary tract infection—Epirubicin—bone cancer	0.000354	0.00385	CcSEcCtD
Gemfibrozil—PPARA—Adipogenesis—RB1—bone cancer	0.00035	0.0043	CbGpPWpGaD
Gemfibrozil—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000349	0.00429	CbGpPWpGaD
Gemfibrozil—Photosensitivity reaction—Doxorubicin—bone cancer	0.000345	0.00375	CcSEcCtD
Gemfibrozil—Hepatobiliary disease—Epirubicin—bone cancer	0.000345	0.00374	CcSEcCtD
Gemfibrozil—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000344	0.00423	CbGpPWpGaD
Gemfibrozil—PPARA—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000343	0.00422	CbGpPWpGaD
Gemfibrozil—Weight decreased—Doxorubicin—bone cancer	0.000342	0.00371	CcSEcCtD
Gemfibrozil—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000336	0.00413	CbGpPWpGaD
Gemfibrozil—Renal failure—Doxorubicin—bone cancer	0.000332	0.0036	CcSEcCtD
Gemfibrozil—Neuropathy peripheral—Doxorubicin—bone cancer	0.000331	0.00359	CcSEcCtD
Gemfibrozil—Jaundice—Doxorubicin—bone cancer	0.000329	0.00357	CcSEcCtD
Gemfibrozil—Rhinitis—Epirubicin—bone cancer	0.000328	0.00356	CcSEcCtD
Gemfibrozil—Urinary tract infection—Doxorubicin—bone cancer	0.000328	0.00356	CcSEcCtD
Gemfibrozil—Eye disorder—Methotrexate—bone cancer	0.000327	0.00355	CcSEcCtD
Gemfibrozil—Hypoaesthesia—Epirubicin—bone cancer	0.000326	0.00353	CcSEcCtD
Gemfibrozil—Asthenia—Cisplatin—bone cancer	0.000325	0.00353	CcSEcCtD
Gemfibrozil—Connective tissue disorder—Epirubicin—bone cancer	0.000322	0.00349	CcSEcCtD
Gemfibrozil—Hepatobiliary disease—Doxorubicin—bone cancer	0.000319	0.00346	CcSEcCtD
Gemfibrozil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000318	0.00391	CbGpPWpGaD
Gemfibrozil—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000317	0.00389	CbGpPWpGaD
Gemfibrozil—Mediastinal disorder—Methotrexate—bone cancer	0.000315	0.00342	CcSEcCtD
Gemfibrozil—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000314	0.00386	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—NDUFA12—bone cancer	0.000311	0.00382	CbGpPWpGaD
Gemfibrozil—Diarrhoea—Cisplatin—bone cancer	0.00031	0.00336	CcSEcCtD
Gemfibrozil—Alopecia—Methotrexate—bone cancer	0.000309	0.00335	CcSEcCtD
Gemfibrozil—Mental disorder—Methotrexate—bone cancer	0.000306	0.00332	CcSEcCtD
Gemfibrozil—Eye disorder—Epirubicin—bone cancer	0.000306	0.00332	CcSEcCtD
Gemfibrozil—Rhinitis—Doxorubicin—bone cancer	0.000304	0.00329	CcSEcCtD
Gemfibrozil—Hypoaesthesia—Doxorubicin—bone cancer	0.000301	0.00327	CcSEcCtD
Gemfibrozil—Dysgeusia—Methotrexate—bone cancer	0.000298	0.00324	CcSEcCtD
Gemfibrozil—Connective tissue disorder—Doxorubicin—bone cancer	0.000298	0.00323	CcSEcCtD
Gemfibrozil—Mediastinal disorder—Epirubicin—bone cancer	0.000295	0.0032	CcSEcCtD
Gemfibrozil—Alopecia—Epirubicin—bone cancer	0.000289	0.00314	CcSEcCtD
Gemfibrozil—Vomiting—Cisplatin—bone cancer	0.000288	0.00312	CcSEcCtD
Gemfibrozil—Vision blurred—Methotrexate—bone cancer	0.000287	0.00311	CcSEcCtD
Gemfibrozil—Mental disorder—Epirubicin—bone cancer	0.000287	0.00311	CcSEcCtD
Gemfibrozil—Rash—Cisplatin—bone cancer	0.000286	0.0031	CcSEcCtD
Gemfibrozil—Dermatitis—Cisplatin—bone cancer	0.000285	0.0031	CcSEcCtD
Gemfibrozil—PPARA—Circadian rythm related genes—CDK4—bone cancer	0.000284	0.00349	CbGpPWpGaD
Gemfibrozil—Eye disorder—Doxorubicin—bone cancer	0.000283	0.00307	CcSEcCtD
Gemfibrozil—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000283	0.00347	CbGpPWpGaD
Gemfibrozil—PPARA—Gene Expression—FUS—bone cancer	0.000282	0.00346	CbGpPWpGaD
Gemfibrozil—Anaemia—Methotrexate—bone cancer	0.000281	0.00305	CcSEcCtD
Gemfibrozil—Flatulence—Epirubicin—bone cancer	0.000281	0.00305	CcSEcCtD
Gemfibrozil—Tension—Epirubicin—bone cancer	0.00028	0.00303	CcSEcCtD
Gemfibrozil—Dysgeusia—Epirubicin—bone cancer	0.000279	0.00303	CcSEcCtD
Gemfibrozil—Nervousness—Epirubicin—bone cancer	0.000277	0.003	CcSEcCtD
Gemfibrozil—Vertigo—Methotrexate—bone cancer	0.000274	0.00297	CcSEcCtD
Gemfibrozil—Mediastinal disorder—Doxorubicin—bone cancer	0.000273	0.00296	CcSEcCtD
Gemfibrozil—Leukopenia—Methotrexate—bone cancer	0.000273	0.00296	CcSEcCtD
Gemfibrozil—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000272	0.00334	CbGpPWpGaD
Gemfibrozil—Nausea—Cisplatin—bone cancer	0.000269	0.00292	CcSEcCtD
Gemfibrozil—Vision blurred—Epirubicin—bone cancer	0.000269	0.00291	CcSEcCtD
Gemfibrozil—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000268	0.0033	CbGpPWpGaD
Gemfibrozil—Alopecia—Doxorubicin—bone cancer	0.000268	0.0029	CcSEcCtD
Gemfibrozil—Cough—Methotrexate—bone cancer	0.000266	0.00288	CcSEcCtD
Gemfibrozil—Mental disorder—Doxorubicin—bone cancer	0.000265	0.00288	CcSEcCtD
Gemfibrozil—Convulsion—Methotrexate—bone cancer	0.000264	0.00286	CcSEcCtD
Gemfibrozil—Anaemia—Epirubicin—bone cancer	0.000263	0.00286	CcSEcCtD
Gemfibrozil—Flatulence—Doxorubicin—bone cancer	0.00026	0.00282	CcSEcCtD
Gemfibrozil—Myalgia—Methotrexate—bone cancer	0.000259	0.00281	CcSEcCtD
Gemfibrozil—Arthralgia—Methotrexate—bone cancer	0.000259	0.00281	CcSEcCtD
Gemfibrozil—Chest pain—Methotrexate—bone cancer	0.000259	0.00281	CcSEcCtD
Gemfibrozil—Tension—Doxorubicin—bone cancer	0.000259	0.00281	CcSEcCtD
Gemfibrozil—Dysgeusia—Doxorubicin—bone cancer	0.000258	0.0028	CcSEcCtD
Gemfibrozil—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000258	0.00317	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—NT5C3A—bone cancer	0.000258	0.00317	CbGpPWpGaD
Gemfibrozil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000257	0.00279	CcSEcCtD
Gemfibrozil—Nervousness—Doxorubicin—bone cancer	0.000256	0.00278	CcSEcCtD
Gemfibrozil—Vertigo—Epirubicin—bone cancer	0.000256	0.00278	CcSEcCtD
Gemfibrozil—Syncope—Epirubicin—bone cancer	0.000256	0.00277	CcSEcCtD
Gemfibrozil—Leukopenia—Epirubicin—bone cancer	0.000255	0.00277	CcSEcCtD
Gemfibrozil—Confusional state—Methotrexate—bone cancer	0.000251	0.00272	CcSEcCtD
Gemfibrozil—Loss of consciousness—Epirubicin—bone cancer	0.00025	0.00272	CcSEcCtD
Gemfibrozil—Cough—Epirubicin—bone cancer	0.000249	0.0027	CcSEcCtD
Gemfibrozil—Anaphylactic shock—Methotrexate—bone cancer	0.000249	0.0027	CcSEcCtD
Gemfibrozil—Vision blurred—Doxorubicin—bone cancer	0.000249	0.0027	CcSEcCtD
Gemfibrozil—Convulsion—Epirubicin—bone cancer	0.000247	0.00268	CcSEcCtD
Gemfibrozil—Nervous system disorder—Methotrexate—bone cancer	0.000244	0.00264	CcSEcCtD
Gemfibrozil—Anaemia—Doxorubicin—bone cancer	0.000244	0.00264	CcSEcCtD
Gemfibrozil—Thrombocytopenia—Methotrexate—bone cancer	0.000243	0.00264	CcSEcCtD
Gemfibrozil—Myalgia—Epirubicin—bone cancer	0.000243	0.00263	CcSEcCtD
Gemfibrozil—Arthralgia—Epirubicin—bone cancer	0.000243	0.00263	CcSEcCtD
Gemfibrozil—Chest pain—Epirubicin—bone cancer	0.000243	0.00263	CcSEcCtD
Gemfibrozil—Skin disorder—Methotrexate—bone cancer	0.000241	0.00262	CcSEcCtD
Gemfibrozil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000241	0.00261	CcSEcCtD
Gemfibrozil—Vertigo—Doxorubicin—bone cancer	0.000237	0.00257	CcSEcCtD
Gemfibrozil—Syncope—Doxorubicin—bone cancer	0.000236	0.00257	CcSEcCtD
Gemfibrozil—Leukopenia—Doxorubicin—bone cancer	0.000236	0.00256	CcSEcCtD
Gemfibrozil—Confusional state—Epirubicin—bone cancer	0.000235	0.00254	CcSEcCtD
Gemfibrozil—Anaphylactic shock—Epirubicin—bone cancer	0.000233	0.00252	CcSEcCtD
Gemfibrozil—Oedema—Epirubicin—bone cancer	0.000233	0.00252	CcSEcCtD
Gemfibrozil—Loss of consciousness—Doxorubicin—bone cancer	0.000232	0.00251	CcSEcCtD
Gemfibrozil—Cough—Doxorubicin—bone cancer	0.00023	0.0025	CcSEcCtD
Gemfibrozil—Shock—Epirubicin—bone cancer	0.000229	0.00248	CcSEcCtD
Gemfibrozil—Convulsion—Doxorubicin—bone cancer	0.000228	0.00248	CcSEcCtD
Gemfibrozil—Nervous system disorder—Epirubicin—bone cancer	0.000228	0.00247	CcSEcCtD
Gemfibrozil—Thrombocytopenia—Epirubicin—bone cancer	0.000228	0.00247	CcSEcCtD
Gemfibrozil—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000226	0.00246	CcSEcCtD
Gemfibrozil—Skin disorder—Epirubicin—bone cancer	0.000226	0.00245	CcSEcCtD
Gemfibrozil—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000225	0.00276	CbGpPWpGaD
Gemfibrozil—Chest pain—Doxorubicin—bone cancer	0.000225	0.00244	CcSEcCtD
Gemfibrozil—Myalgia—Doxorubicin—bone cancer	0.000225	0.00244	CcSEcCtD
Gemfibrozil—Arthralgia—Doxorubicin—bone cancer	0.000225	0.00244	CcSEcCtD
Gemfibrozil—Paraesthesia—Methotrexate—bone cancer	0.000223	0.00242	CcSEcCtD
Gemfibrozil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000223	0.00242	CcSEcCtD
Gemfibrozil—Somnolence—Methotrexate—bone cancer	0.000221	0.0024	CcSEcCtD
Gemfibrozil—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00022	0.00271	CbGpPWpGaD
Gemfibrozil—Dyspepsia—Methotrexate—bone cancer	0.000219	0.00237	CcSEcCtD
Gemfibrozil—Confusional state—Doxorubicin—bone cancer	0.000217	0.00235	CcSEcCtD
Gemfibrozil—Oedema—Doxorubicin—bone cancer	0.000215	0.00233	CcSEcCtD
Gemfibrozil—Anaphylactic shock—Doxorubicin—bone cancer	0.000215	0.00233	CcSEcCtD
Gemfibrozil—Gastrointestinal disorder—Methotrexate—bone cancer	0.000215	0.00233	CcSEcCtD
Gemfibrozil—Fatigue—Methotrexate—bone cancer	0.000214	0.00232	CcSEcCtD
Gemfibrozil—Pain—Methotrexate—bone cancer	0.000213	0.00231	CcSEcCtD
Gemfibrozil—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000212	0.0023	CcSEcCtD
Gemfibrozil—Shock—Doxorubicin—bone cancer	0.000212	0.0023	CcSEcCtD
Gemfibrozil—Nervous system disorder—Doxorubicin—bone cancer	0.000211	0.00229	CcSEcCtD
Gemfibrozil—Thrombocytopenia—Doxorubicin—bone cancer	0.000211	0.00229	CcSEcCtD
Gemfibrozil—Skin disorder—Doxorubicin—bone cancer	0.000209	0.00227	CcSEcCtD
Gemfibrozil—Paraesthesia—Epirubicin—bone cancer	0.000209	0.00227	CcSEcCtD
Gemfibrozil—Somnolence—Epirubicin—bone cancer	0.000207	0.00224	CcSEcCtD
Gemfibrozil—Feeling abnormal—Methotrexate—bone cancer	0.000205	0.00222	CcSEcCtD
Gemfibrozil—Dyspepsia—Epirubicin—bone cancer	0.000205	0.00222	CcSEcCtD
Gemfibrozil—Gastrointestinal pain—Methotrexate—bone cancer	0.000203	0.0022	CcSEcCtD
Gemfibrozil—Gastrointestinal disorder—Epirubicin—bone cancer	0.000201	0.00218	CcSEcCtD
Gemfibrozil—Fatigue—Epirubicin—bone cancer	0.000201	0.00218	CcSEcCtD
Gemfibrozil—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.0002	0.00246	CbGpPWpGaD
Gemfibrozil—Pain—Epirubicin—bone cancer	0.000199	0.00216	CcSEcCtD
Gemfibrozil—Constipation—Epirubicin—bone cancer	0.000199	0.00216	CcSEcCtD
Gemfibrozil—Urticaria—Methotrexate—bone cancer	0.000197	0.00214	CcSEcCtD
Gemfibrozil—Abdominal pain—Methotrexate—bone cancer	0.000196	0.00213	CcSEcCtD
Gemfibrozil—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000196	0.00213	CcSEcCtD
Gemfibrozil—PPARA—Gene Expression—NR1I2—bone cancer	0.000195	0.0024	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000194	0.00238	CbGpPWpGaD
Gemfibrozil—Paraesthesia—Doxorubicin—bone cancer	0.000193	0.0021	CcSEcCtD
Gemfibrozil—Feeling abnormal—Epirubicin—bone cancer	0.000192	0.00208	CcSEcCtD
Gemfibrozil—Somnolence—Doxorubicin—bone cancer	0.000191	0.00208	CcSEcCtD
Gemfibrozil—Gastrointestinal pain—Epirubicin—bone cancer	0.00019	0.00206	CcSEcCtD
Gemfibrozil—Dyspepsia—Doxorubicin—bone cancer	0.000189	0.00206	CcSEcCtD
Gemfibrozil—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000186	0.00202	CcSEcCtD
Gemfibrozil—Fatigue—Doxorubicin—bone cancer	0.000186	0.00201	CcSEcCtD
Gemfibrozil—Urticaria—Epirubicin—bone cancer	0.000185	0.002	CcSEcCtD
Gemfibrozil—Pain—Doxorubicin—bone cancer	0.000184	0.002	CcSEcCtD
Gemfibrozil—Constipation—Doxorubicin—bone cancer	0.000184	0.002	CcSEcCtD
Gemfibrozil—Abdominal pain—Epirubicin—bone cancer	0.000184	0.00199	CcSEcCtD
Gemfibrozil—PPARA—Circadian rythm related genes—JUN—bone cancer	0.000183	0.00225	CbGpPWpGaD
Gemfibrozil—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000181	0.00223	CbGpPWpGaD
Gemfibrozil—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000179	0.0022	CbGpPWpGaD
Gemfibrozil—Asthenia—Methotrexate—bone cancer	0.000178	0.00193	CcSEcCtD
Gemfibrozil—Feeling abnormal—Doxorubicin—bone cancer	0.000177	0.00192	CcSEcCtD
Gemfibrozil—Gastrointestinal pain—Doxorubicin—bone cancer	0.000176	0.00191	CcSEcCtD
Gemfibrozil—Pruritus—Methotrexate—bone cancer	0.000176	0.00191	CcSEcCtD
Gemfibrozil—SLCO1B1—Metabolism—NDUFA12—bone cancer	0.000176	0.00216	CbGpPWpGaD
Gemfibrozil—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000171	0.0021	CbGpPWpGaD
Gemfibrozil—Urticaria—Doxorubicin—bone cancer	0.000171	0.00185	CcSEcCtD
Gemfibrozil—Abdominal pain—Doxorubicin—bone cancer	0.00017	0.00185	CcSEcCtD
Gemfibrozil—Diarrhoea—Methotrexate—bone cancer	0.00017	0.00184	CcSEcCtD
Gemfibrozil—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000168	0.00207	CbGpPWpGaD
Gemfibrozil—Asthenia—Epirubicin—bone cancer	0.000167	0.00181	CcSEcCtD
Gemfibrozil—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000166	0.00204	CbGpPWpGaD
Gemfibrozil—Pruritus—Epirubicin—bone cancer	0.000165	0.00179	CcSEcCtD
Gemfibrozil—Dizziness—Methotrexate—bone cancer	0.000164	0.00178	CcSEcCtD
Gemfibrozil—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000163	0.002	CbGpPWpGaD
Gemfibrozil—Diarrhoea—Epirubicin—bone cancer	0.000159	0.00173	CcSEcCtD
Gemfibrozil—Vomiting—Methotrexate—bone cancer	0.000158	0.00171	CcSEcCtD
Gemfibrozil—Rash—Methotrexate—bone cancer	0.000157	0.0017	CcSEcCtD
Gemfibrozil—Dermatitis—Methotrexate—bone cancer	0.000157	0.0017	CcSEcCtD
Gemfibrozil—Headache—Methotrexate—bone cancer	0.000156	0.00169	CcSEcCtD
Gemfibrozil—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000155	0.0019	CbGpPWpGaD
Gemfibrozil—Asthenia—Doxorubicin—bone cancer	0.000154	0.00168	CcSEcCtD
Gemfibrozil—Dizziness—Epirubicin—bone cancer	0.000154	0.00167	CcSEcCtD
Gemfibrozil—Pruritus—Doxorubicin—bone cancer	0.000152	0.00165	CcSEcCtD
Gemfibrozil—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.00015	0.00185	CbGpPWpGaD
Gemfibrozil—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000149	0.00183	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000148	0.00182	CbGpPWpGaD
Gemfibrozil—Vomiting—Epirubicin—bone cancer	0.000148	0.0016	CcSEcCtD
Gemfibrozil—Nausea—Methotrexate—bone cancer	0.000148	0.0016	CcSEcCtD
Gemfibrozil—Diarrhoea—Doxorubicin—bone cancer	0.000147	0.0016	CcSEcCtD
Gemfibrozil—Rash—Epirubicin—bone cancer	0.000147	0.00159	CcSEcCtD
Gemfibrozil—Dermatitis—Epirubicin—bone cancer	0.000147	0.00159	CcSEcCtD
Gemfibrozil—Headache—Epirubicin—bone cancer	0.000146	0.00158	CcSEcCtD
Gemfibrozil—SLCO1B1—Metabolism—NT5C3A—bone cancer	0.000145	0.00179	CbGpPWpGaD
Gemfibrozil—PPARA—Gene Expression—EIF2S1—bone cancer	0.000144	0.00177	CbGpPWpGaD
Gemfibrozil—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.000144	0.00177	CbGpPWpGaD
Gemfibrozil—Dizziness—Doxorubicin—bone cancer	0.000142	0.00154	CcSEcCtD
Gemfibrozil—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000142	0.00174	CbGpPWpGaD
Gemfibrozil—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000139	0.00171	CbGpPWpGaD
Gemfibrozil—PPARA—Developmental Biology—MET—bone cancer	0.000138	0.0017	CbGpPWpGaD
Gemfibrozil—PPARA—Developmental Biology—CDK4—bone cancer	0.000138	0.0017	CbGpPWpGaD
Gemfibrozil—Nausea—Epirubicin—bone cancer	0.000138	0.0015	CcSEcCtD
Gemfibrozil—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000137	0.00168	CbGpPWpGaD
Gemfibrozil—Vomiting—Doxorubicin—bone cancer	0.000137	0.00148	CcSEcCtD
Gemfibrozil—Rash—Doxorubicin—bone cancer	0.000136	0.00147	CcSEcCtD
Gemfibrozil—Dermatitis—Doxorubicin—bone cancer	0.000136	0.00147	CcSEcCtD
Gemfibrozil—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000135	0.00166	CbGpPWpGaD
Gemfibrozil—Headache—Doxorubicin—bone cancer	0.000135	0.00146	CcSEcCtD
Gemfibrozil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000134	0.00165	CbGpPWpGaD
Gemfibrozil—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000128	0.00158	CbGpPWpGaD
Gemfibrozil—Nausea—Doxorubicin—bone cancer	0.000128	0.00139	CcSEcCtD
Gemfibrozil—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000127	0.00156	CbGpPWpGaD
Gemfibrozil—PPARA—Gene Expression—EZH2—bone cancer	0.000125	0.00154	CbGpPWpGaD
Gemfibrozil—PPARA—Circadian rythm related genes—TP53—bone cancer	0.000121	0.00148	CbGpPWpGaD
Gemfibrozil—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000119	0.00147	CbGpPWpGaD
Gemfibrozil—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000117	0.00144	CbGpPWpGaD
Gemfibrozil—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000117	0.00144	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000116	0.00142	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000115	0.00142	CbGpPWpGaD
Gemfibrozil—PPARA—Developmental Biology—MMP2—bone cancer	0.000115	0.00142	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—ENO2—bone cancer	0.000113	0.00139	CbGpPWpGaD
Gemfibrozil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000106	0.0013	CbGpPWpGaD
Gemfibrozil—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000106	0.0013	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—DHFR—bone cancer	0.000105	0.00129	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—NDUFA12—bone cancer	0.000101	0.00124	CbGpPWpGaD
Gemfibrozil—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.0001	0.00123	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	9.87e-05	0.00121	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—GNA11—bone cancer	9.79e-05	0.0012	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—NDUFA12—bone cancer	9e-05	0.00111	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—CYP3A4—bone cancer	8.88e-05	0.00109	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.83e-05	0.00108	CbGpPWpGaD
Gemfibrozil—PPARA—Developmental Biology—MMP9—bone cancer	8.67e-05	0.00107	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—NT5C3A—bone cancer	8.36e-05	0.00103	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—NDUFA12—bone cancer	8.21e-05	0.00101	CbGpPWpGaD
Gemfibrozil—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.73e-05	0.000949	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.62e-05	0.000936	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—GSTP1—bone cancer	7.59e-05	0.000933	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—NT5C3A—bone cancer	7.46e-05	0.000917	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—NDUFA12—bone cancer	7.02e-05	0.000862	CbGpPWpGaD
Gemfibrozil—PPARA—Developmental Biology—EGFR—bone cancer	7.01e-05	0.000861	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—NT5C3A—bone cancer	6.8e-05	0.000836	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Metabolism—ENO2—bone cancer	6.37e-05	0.000783	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Metabolism—DHFR—bone cancer	5.91e-05	0.000726	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—NT5C3A—bone cancer	5.81e-05	0.000714	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Metabolism—GNA11—bone cancer	5.52e-05	0.000679	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metabolism—NDUFA12—bone cancer	5.41e-05	0.000665	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Metabolism—CYP3A4—bone cancer	5.01e-05	0.000615	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.98e-05	0.000612	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metabolism—NT5C3A—bone cancer	4.49e-05	0.000551	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Metabolism—GSTP1—bone cancer	4.28e-05	0.000526	CbGpPWpGaD
Gemfibrozil—PPARA—Metabolism—PTGS2—bone cancer	3.93e-05	0.000483	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—ENO2—bone cancer	3.66e-05	0.00045	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—DHFR—bone cancer	3.4e-05	0.000417	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—ENO2—bone cancer	3.27e-05	0.000402	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—GNA11—bone cancer	3.17e-05	0.00039	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—DHFR—bone cancer	3.03e-05	0.000373	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—ENO2—bone cancer	2.98e-05	0.000366	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—CYP3A4—bone cancer	2.88e-05	0.000354	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.86e-05	0.000352	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—GNA11—bone cancer	2.83e-05	0.000348	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—DHFR—bone cancer	2.76e-05	0.00034	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—GNA11—bone cancer	2.58e-05	0.000317	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—CYP3A4—bone cancer	2.57e-05	0.000316	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.56e-05	0.000314	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—ENO2—bone cancer	2.55e-05	0.000313	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—GSTP1—bone cancer	2.46e-05	0.000302	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—DHFR—bone cancer	2.36e-05	0.00029	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—CYP3A4—bone cancer	2.34e-05	0.000288	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.33e-05	0.000286	CbGpPWpGaD
Gemfibrozil—SLCO1B1—Metabolism—PTGS2—bone cancer	2.22e-05	0.000273	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—GNA11—bone cancer	2.21e-05	0.000271	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—GSTP1—bone cancer	2.2e-05	0.00027	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—GSTP1—bone cancer	2e-05	0.000246	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—CYP3A4—bone cancer	2e-05	0.000246	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.99e-05	0.000245	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metabolism—ENO2—bone cancer	1.97e-05	0.000241	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metabolism—DHFR—bone cancer	1.82e-05	0.000224	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—GSTP1—bone cancer	1.71e-05	0.00021	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metabolism—GNA11—bone cancer	1.7e-05	0.000209	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metabolism—GSTP1—bone cancer	1.32e-05	0.000162	CbGpPWpGaD
Gemfibrozil—CYP2C8—Metabolism—PTGS2—bone cancer	1.28e-05	0.000157	CbGpPWpGaD
Gemfibrozil—CYP2C19—Metabolism—PTGS2—bone cancer	1.14e-05	0.00014	CbGpPWpGaD
Gemfibrozil—CYP2C9—Metabolism—PTGS2—bone cancer	1.04e-05	0.000128	CbGpPWpGaD
Gemfibrozil—CYP1A2—Metabolism—PTGS2—bone cancer	8.87e-06	0.000109	CbGpPWpGaD
Gemfibrozil—CYP3A4—Metabolism—PTGS2—bone cancer	6.84e-06	8.41e-05	CbGpPWpGaD
